Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia

Leuk Res. 2023 Apr:127:107039. doi: 10.1016/j.leukres.2023.107039. Epub 2023 Feb 12.
No abstract available

Keywords: BCL-2 inhibitors; BCR-ABL1 kinase inhibitors; Flumatinib; Hypomethylating agents; Olverembatinib.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / therapeutic use
  • Blast Crisis* / drug therapy
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Fusion Proteins, bcr-abl
  • Humans
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Tyrosine Kinase Inhibitors*

Substances

  • venetoclax
  • Tyrosine Kinase Inhibitors
  • Azacitidine
  • Bridged Bicyclo Compounds, Heterocyclic
  • Fusion Proteins, bcr-abl
  • Protein Kinase Inhibitors